Summary: The results of randomized, placebo-controlled trials have clearly demonstrated the efficacy of mepolizumab in improving disease control and the quality of life in cohorts of patients suffering from severe, eosinophilic asthma. The observed key criteria for good response to treatment include reduced use of emergency medication, systemic and inhaled corticosteroid consumption, and a significant reduction in the risk of exacerbation. Recently published reports confirm these findings, proving the long-term safety and efficacy of mepolizumab treatment. Mepolizumab is available to patients with asthma in Poland as part of the therapeutic program for the treatment of severe asthma. If the diagnosis of severe bronchial asthma is suspected, after careful differential diagnosis and the exclusion of other potentially modifiable factors affecting the course of the disease, it is worth considering referring such a patient to the reference center for the inclusion of biological therapy.